ApoGen raises additional $4M, adds three biotech vets in pursuit of better cancer treatment
Biotech startup ApoGen, which is researching solutions to drug-resistant cancers, is moving into a new phase of development. The company announced Thursday that it has raised an additional $4 million as part of its series A round, bringing the total in that round to $11 million. The additional funding comes from M Ventures, the venture investment arm of German multinational healthcare company Merck KGaA, which shares a name with the American drug manufacturer. ApoGen said the funding will help the startup grow its team and establish its first independent lab and office in Seattle. The company was incubated by Accelerator… Read More